Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer
- 31 December 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (5) , 709-713
- https://doi.org/10.1016/0959-8049(94)00516-8
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy—a phase II study of the EORTC gynaecological cancer cooperative groupEuropean Journal Of Cancer, 1994
- Salvage Intraperitoneal Therapy of Ovarian Cancer Employing Cisplatin and Etoposide: A Gynecologic Oncology Group StudyGynecologic Oncology, 1993
- High-Dose Biweekly Intraperitoneal Cisplatin: An Effective Way to Increase Cisplatin Dose IntensityGynecologic Oncology, 1993
- Intraperitoneal High-Dose Cisplatin and Etoposide with Systemic Thiosulfate Protection in Second-Line Treatment of Advanced Ovarian CancerGynecologic Oncology, 1993
- Intraperitoneal chemotherapy in the management of ovarian cancerCancer, 1993
- A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancerEuropean Journal Of Cancer, 1992
- Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancerGynecologic Oncology, 1990
- Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatmentCancer Chemotherapy and Pharmacology, 1990
- Evaluation of treatment and survival after positive second-look laparotomyGynecologic Oncology, 1988
- COMPLETE REMISSION AT LAPAROTOMY: STILL A GOLD STANDARD IN OVARIAN CANCER?The Lancet, 1986